Hypothyroidism: Clinical Pharmacology and Management

In primary hypothyroidism, the thyroid gland fails and thyroid-stimulating hormone rises as the pituitary responds to inadequate hormone output. Hashimoto's thyroiditis is the dominant cause in iodine-sufficient populations. Post-ablative hypothyroidism after radioactive iodine or thyroidectomy is the second most common cause; levothyroxine requirements are predictable and often full replacement from initiation. Iatrogenic causes include thionamide overtreatment, lithium, amiodarone, and immune checkpoint inhibitors.

In primary hypothyroidism, thyroid-stimulating hormone is both the diagnostic endpoint and the monitoring tool. A thyroid-stimulating hormone above the reference range with a low or low-normal free thyroxine confirms the diagnosis, and thyroid-stimulating hormone normalizes reliably once adequate levothyroxine replacement is achieved.

Central hypothyroidism arises from pituitary or hypothalamic disease and presents with a distinctly different biochemical pattern: thyroid-stimulating hormone is low, inappropriately normal, or only mildly elevated despite a subnormal free thyroxine, because the pituitary cannot mount a normal response to hormone deficiency. Common causes include pituitary macroadenoma, pituitary surgery or radiation, traumatic brain injury, Sheehan's syndrome, and infiltrative diseases such as sarcoidosis and hemochromatosis.

In central hypothyroidism, free thyroxine — not thyroid-stimulating hormone — is the monitoring endpoint. The target is free thyroxine in the upper half of the reference range, verified at least 6 weeks after any dose change. Using thyroid-stimulating hormone as the endpoint in central hypothyroidism leads to systematic under-replacement, because thyroid-stimulating hormone remains low or normal even at subtherapeutic doses.

Subclinical hypothyroidism is defined as a thyroid-stimulating hormone above the upper reference limit with a normal free thyroxine. Treatment is recommended when thyroid-stimulating hormone exceeds 10 mIU/L regardless of symptoms, and in younger patients (under 65) with thyroid-stimulating hormone 4.5–10 mIU/L who have symptoms, positive anti-thyroid peroxidase antibodies, dyslipidemia, or pregnancy risk. In elderly patients over 70 with thyroid-stimulating hormone 4.5–10 mIU/L and no symptoms, the TRUST trial demonstrated no benefit of levothyroxine on quality of life, fatigue, or cognitive function; watchful waiting with repeat testing in 3–6 months is appropriate.

Levothyroxine increases cardiac oxygen demand and heart rate. Abrupt full replacement in patients with underlying coronary artery disease can precipitate angina, myocardial infarction, or arrhythmia. The standard approach is to initiate at 12.5–25 micrograms per day and uptitrate by 12.5–25 micrograms every 4–6 weeks, targeting the lower end of the age-appropriate thyroid-stimulating hormone range. There is no absolute contraindication to levothyroxine in cardiac disease, but the titration must be gradual and monitored. If a patient with severe coronary artery disease requires urgent cardiac intervention, it should not be delayed for thyroid optimization; hypothyroidism correction proceeds postoperatively.

Maternal thyroxine is the sole source of thyroid hormone for the fetus during the first trimester, before fetal thyroid development is complete at approximately 18–20 weeks. Adequate maternal thyroxine is essential for fetal brain development; even subclinical maternal hypothyroidism in the first trimester is associated with impaired neurodevelopmental outcomes.

Levothyroxine demand increases by 30–50% during pregnancy, driven by rising estrogen-induced thyroxine-binding globulin production, placental type 3 deiodinase activity consuming maternal thyroxine, and increased renal iodine clearance. Women with pre-existing hypothyroidism almost universally require dose escalation — typically 25–30% above pre-pregnancy dose — beginning as soon as pregnancy is confirmed. Thyroid-stimulating hormone should be monitored every 4 weeks in the first trimester and every 4–6 weeks thereafter. Women planning pregnancy should achieve thyroid-stimulating hormone below 2.5 mIU/L before conception.

Malabsorptive conditions including celiac disease, short bowel syndrome, and inflammatory bowel disease flares typically require 20–30% higher levothyroxine doses and benefit from switching to liquid formulations. Roux-en-Y gastric bypass bypasses the proximal small intestine where most levothyroxine absorption occurs; post-surgical patients often require 30–50% dose increases and should have thyroid-stimulating hormone monitored 6–8 weeks after surgery.

The clinical picture combines depressed consciousness (from somnolence to stupor), hypothermia, hypoventilation, bradycardia, hyponatremia, and hypoglycemia. Myxedema coma most often occurs in elderly women with undiagnosed or inadequately treated hypothyroidism who decompensate when acute illness exhausts their physiological reserve. Common precipitants include infection (pneumonia and urinary tract infection are most frequent), cold exposure, sedatives, opioids, anesthetics, trauma, stroke, and levothyroxine non-adherence.

Intravenous thyroid hormone is required because gastrointestinal absorption is unreliable in a comatose or hemodynamically unstable patient with reduced gut motility. The standard protocol uses intravenous levothyroxine at a loading dose of 300–500 micrograms, followed by 50–100 micrograms intravenously daily. The large loading dose rapidly saturates the expanded volume of distribution of thyroxine and restores circulating hormone levels; the dose is reduced in elderly patients or those with ischemic heart disease.

Adjunctive intravenous liothyronine (triiodothyronine) is used at many centers on the rationale that impaired peripheral thyroxine-to-triiodothyronine conversion in severe illness makes direct triiodothyronine repletion valuable. However, intravenous triiodothyronine carries arrhythmia risk, and randomized trial evidence for mortality benefit is lacking. Intravenous glucocorticoids (hydrocortisone 50–100 mg every 6–8 hours) are given empirically in all cases of myxedema coma because adrenal insufficiency frequently coexists, particularly in patients with pituitary or autoimmune thyroid disease, and glucocorticoid deficiency can cause cardiovascular collapse when thyroid hormone is replaced without cortisol support.